Abstracts Archive - Page 1685 of 2425 - ACR Meeting Abstracts

Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁵Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
julien henry¹, stéphane pavy², Jacques Gottenberg³, rakiba belkhir⁴, Stéphanie Rouanet⁵, Jérémie Sellam⁶, Xavier Mariette⁷ and raphaèle seror⁴, ¹departement of rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ³Hautepierre, Strasbourg, France, ⁴Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁵Biostatistics, Roche France, Boulogne-Billancourt, France, ⁶Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁷Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…
Abstract Number: 3200 • 2015 ACR/ARHP Annual Meeting
Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model
Astrid Rasmussen¹, Christopher J Lessard², Indra Adrianto¹, Graham B. Wiley¹, Donald U Stone^3,4, C. Erick Kaufman⁵, Lida Radfar⁶, David M. Lewis⁷, Stephen K Young⁸, Michael H. Weisman⁹, Daniel J Wallace¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², John A. Ice¹, Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, Jennifer A. Kelly²⁰, Kiely Grundahl²¹, Kimberly Hefner²², R. Hal Scofield^1,23,24 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁴Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁵College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ²²Hefner Eye Care and Optical Center, Oklahoma City, OK, ²³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Autoimmune diseases are often preceded by subclinical serologic and functional abnormalities that predate diagnosis by several years. The insidious and progressive nature of these…
Abstract Number: 3201 • 2015 ACR/ARHP Annual Meeting
IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.A. Kruize¹, A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake^1,2 and J.A.G. van Roon^1,6, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA, ⁶Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In primary Sjögren’s syndrome (pSS) B cell hyperactivity including autoantibody secretion and lymphoma development are hallmark immunopathological features. Specific lymphoid organization (including germinal centers)…
Abstract Number: 3202 • 2015 ACR/ARHP Annual Meeting
Functional Anti-Muscarinic Receptor-3 Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjögren’s Syndrome
Syed M.S. Quadri^1,2, Kristi A. Koelsch³, Valerie Harris⁴, Biji T Kurien⁵ and R. Hal Scofield⁶, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune inflammatory disease characterized by bilateral hypofunction of lacrimal and salivary glands leading to keratoconjuctivitis and xerostomia. The…
Abstract Number: 3203 • 2015 ACR/ARHP Annual Meeting
The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjögren’s Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
E. William St.Clair¹, Alan N. Baer², Ghaith Noaiseh³, Anne Parke⁴, Andreea Coca⁵, Tammy Utset⁶, Mark C. Genovese⁷, Daniel J Wallace⁸, James McNamara⁹, Karen Boyle¹⁰, Lynette Keyes-Elstein¹⁰, Nathalie Franchimont¹¹, Judith A James¹² and for the Autoimmunity Centers of Excellence supported by a grant from NIAID 5U19-AI056363, ¹Medicine, Duke University, Durham, NC, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Connecticut, Farmington, CT, ⁵University of Rochester Medical Center, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁸Cedars-Sinai Medical Center, West Hollywood, CA, ⁹NIAID/NIH, Bethesda, MD, ¹⁰Rho Federal Systems, Inc., Chapel Hill, NC, ¹¹Biogen, Cambridge, MA, ¹²OMRF, OU, Oklahoma City, OK
Background/Purpose: Primary Sjögren’s syndrome (pSjS) is characterized by chronic inflammation of the lacrimal and salivary glands, as well as frequent extraglandular involvement and increased risk…
Abstract Number: 3204 • 2015 ACR/ARHP Annual Meeting
Hypoechoic Lesions on Parotid Gland Ultrasound Are a Surrogate Marker of Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy in Sjögren’s Syndrome
Thomas Grader-Beck¹, Joel Fradin², Jean Kim³, Esen Akpek⁴, Brendan Antiochos⁵, Julius Birnbaum⁶ and Alan N. Baer⁷, ¹Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ³Otolaryngology, Head & Neck Surgery, Johns Hopkins University, Baltimore, MD, ⁴Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine-Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To determine whether hypoechoic lesions on parotid gland ultrasound can serve as a surrogate marker for a focus score ≥1 on minor salivary gland…
Abstract Number: 3205 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept or Rituximab Targets T Follicular Helper Cells in Patients with Primary Sjogren s Syndrome
Gwenny M. Verstappen¹, Petra M. Meiners², Odilia B.J. Corneth³, Rudi W. Hendriks³, Arjan Vissink⁴, Frans G.M. Kroese⁵ and Hendrika Bootsma⁵, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ⁴Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: T cell-dependent B cell hyperactivity is a characteristic pathogenetic feature of primary Sjögren’s syndrome (pSS). This is illustrated by the finding that treatment of…
Abstract Number: 3206 • 2015 ACR/ARHP Annual Meeting
Inflammation on MRI in Sacroiliac-Joints and Spine Is Longitudinally Related to Disease Activity in Male but Not in Female Patients with Axial Spondyloarthritis: 2-Year Data from the DESIR Cohort
Victoria Navarro-Compán¹, Sofia Ramiro², Robert B. M. Landewé³, Maxime Dougados⁴, Corinne Miceli-Richard⁵, Pascal Richette⁶ and Désirée van der Heijde⁷, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁴Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁵Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁶Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA), clinical disease activity measures (DA) have been longitudinally related to radiographic progression. Interestingly, a gender disparity has been…
Abstract Number: 3207 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis
Deepak R. Jadon¹, Raj Sengupta¹, Alison L Nightingale², Mark Lindsay³, Eleanor Korendowych¹, Graham Robinson⁴, Amelia Jobling⁵, Gavin Shaddick⁶, Anne Barton⁷ and Neil J. McHugh⁸, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Royal United Hospital, Bath, United Kingdom, ⁵Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁶Department of Mathematics, University of Bath, Bath, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁸Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: Little is known of the characteristics of psoriatic spondyloarthritis (PsSpA). A study was conducted to determine the: (i) prevalence of PsSpA in a psoriatic…
Abstract Number: 3208 • 2015 ACR/ARHP Annual Meeting
Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the DESIR Cohort
Sofia Ramiro¹, Désirée van der Heijde¹, Rosaline van den Berg², Victoria Navarro-Compán³, Antoine Feydy⁴, Maria-Antonietta d'Agostino⁵, Damien Loeuille⁶, Maxime Dougados⁷, Monique Reijnierse⁸ and Pascal Claudepierre⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, University Hospital La Paz, Madrid, Spain, ⁴Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France, ⁵Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶Rheumatology, Nancy University Hospital, Nancy, France, ⁷Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁸Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁹Rheumatology, Université Paris Est Créteil, Créteil, France
Background/Purpose: The development of radiographic damage over time has been investigated in patients with AS, but not yet in early axial spondyloarthritis (axSpA). We have…
Abstract Number: 3209 • 2015 ACR/ARHP Annual Meeting
Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Psoriatic Arthritis Patients in Clinical Remission
Josefina Marin^1,2, M Laura Acosta-Felquer², Leandro Ferreyra-Garrot³, Erika Catay⁴, Javier Rosa⁵, Santiago Ruta², Mirtha Sabelli², Ricardo Garcia-Monaco Sr.⁶ and Enrique R. Soriano⁷, ¹Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Internal Medicine, Argentina, Buenos Aires, Argentina, ⁴Salguero 569 7 35, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Ultrasound has been shown to detect subclinical synovitis in in rheumatoid arthritis and psoriatic arthritis (PsA in clinical remission.). The value of power Doppler…
Abstract Number: 3210 • 2015 ACR/ARHP Annual Meeting
Evaluation of Sacroiliac Joint Radiographs in Patients with Chronic Low Back Pain: Is Erosion the Main Driver of Interreader Disagreement?
Alice Ashouri Christiansen^1,2, Oliver Hendricks^1,2, Dorota Kuettel¹, Kim Hørslev-Petersen^1,2, Anne Grethe Jurik^2,3,4, Steen Nielsen¹, Kaspar Rufibach⁵, Anne Gitte Loft^6,7, Susanne Juhl Pedersen^8,9, Louise Thuesen Hermansen^1,2, Mikkel Østergaard^8,10, Bodil Arnbak^2,4, Claus Manniche^2,4 and Ulrich Weber^1,2, ¹Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ²Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ³Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Hospital Lillebaelt, Spine Centre of Southern Denmark, Middelfart, Denmark, ⁵rePROstat, Basel, Switzerland, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁹Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark, ¹⁰Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark
Background/Purpose: Evaluation of sacroiliac joints (SIJ) on pelvic radiographs according to the modified New York criteria (mNYc) is considered the gold standard for classification of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].